

PEOPLE

Richard T. Daly has been named to the board of directors of Visible Genetics (Toronto, Ontario, Canada). He is founder, chairman, and CEO of Clinical Partners, Inc., which provides therapy-specific management of HIV and AIDS patients for employers and managed healthcare organizations in California and Texas.

Shaman Pharmaceuticals (South San Francisco, CA) has announced that Stephanie C. Diaz has joined the company as vice president and CFO. Previously, she held the position of director of finance at Hyseq.

Atlantic Pharmaceuticals (Raleigh, NC) has announced the election of **Robert A. Fildes** as chairman of the board of directors. Dr. Fildes was appointed to the board in October 1997, having previously served as chairman and CEO of Scotgen Biopharmaceuticals, president and CEO of Cetus, and president of Biogen.

Invitrogen (Carlsbad, CA) has named James R. Glynn to the position of senior vice president/CFO and member of the board of directors, and Lewis J. Shuster to the board of directors. Mr. Glynn comes to Invitrogen from Matrix Pharmaceutical, where he served as COO, CFO, and as a member of the board. Mr. Shuster is executive vice president, corporate development and CFO of Pharmacopeia.


Steven D. Goldby has been named chairman and CEO of Symyx Technologies (Santa Clara, CA), replacing Alejandro Zaffaroni, who will continue as a member of the board. Mr. Goldby was most recently at MDL Information Systems, where he has served as CEO since 1987. He will remain a nonexecutive chairman at MDL.

Andaris (Nottingham, UK) has announced that lead founder David Heath is retiring as chairman to become a nonexecutive director and consultant to the company. In addition, Stuart Collinson has been appointed as CEO, and Gordon Hall has been named nonexecutive chairman. Dr. Collinson joins Andaris from Glaxo Wellcome, where he was most recently therapy area director for the company's hospital and critical care business. Mr. Hall was previously managing director of Shield Diagnostics.

Erik Hornnaess has been elected to the board of supervisory directors of Qiagen NV (Venlo, Netherlands). Mr. Hornnaess is the former area vice president of Abbott Laboratories' diagnostics division in Europe, Middle East, and Africa, and currently serves as chairman of the board for Axis Biochemicals, Norway, and as nonexecutive director of Radiometer A/S, Denmark, Shields Diagnostics, Scotland, Orsys/Ilex, Israel, and Alpharma and APL Inc. in the US.

Genentech (South San Francisco, CA) has announced the promotion of Sean A. Johnston to vice president, intellectual property. Mr. Johnston joined Genentech in October 1990 as patent counsel, and is currently associate general counsel and manager of patent litigation.

Douglas C. Lane has been appointed president and CEO of Strata Biosciences (Alameda, CA). He was most recently vice president of genomic research at the prostate cancer foundation capCURE, and



Genzyme Transgenics (Framingham, MA) has appointed Sandra Nusinoff Lehrman president and CEO, succeeding James Geraghty. Mr. Geraghty will remain chairman of Genzyme Transgenics, and will become president of Genzyme Therapeutics Europe. Ms. Lehrman most recently held the position of president and COO at Cytotherapeutics.

J. Joseph Marr has been appointed president and CEO of ImmuLogic (Waltham, MA). Dr. Marr joined ImmuLogic as executive vice president for research in July 1996, and was most recently president and COO.



Microscience Ltd. (London) has named Rod Richards its new CEO. Most recently, Mr. Richards managed part of Glaxo Wellcome's global business development division.

Lidak Pharmaceuticals (San Diego, CA) has named George Rutland chairman. Mr. Rutland is also the chairman, CEO, and a director of Tiapan Corp., a management consulting and investment company. He replaces William Jenkins, who has served as chairman since January, but is now an outgoing director following a recent board election. Megabios (Burlingame, CA) has announced the appointment of **Bennet** Weintraub as chief financial officer and vice president of finance. Previously, Mr. Weintraub was CFO and vice president of finance and administra-



tion at Technology Modeling Associates.

Michael M. Wick has been named president and COO of Telik (South San Francisco, CA), and has been elected to the company's board of directors. Dr. Wick joined the company last December as executive vice president, R&D, and COO.

Former US Secretary of Agriculture Clayton K. Yeutter has been elected to the board of directors of Mycogen (San Diego, CA) to serve until the next annual meeting. He replaces Roy M. Barbee, who resigned from the board. Mr. Yeutter served as Secretary of Agriculture under President George Bush from February 1989 to February 1991, and as Counselor to the President for Domestic Policy in 1992.

